Dapagliflozin Misses in COVID-19 but Intriguing Signal of Benefit Dapagliflozin Misses in COVID-19 but Intriguing Signal of Benefit
The SGLT2 inhibitor dapagliflozin was not associated with significant benefit in COVID-19 patients but came close in the DARE-19 trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 18, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Dapagliflozin did not significantly reduce organ failure or death in high-risk patients hospitalized
(American College of Cardiology) Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 who are at high risk of developing serious complications compared to placebo, according to data presented at the American College of Cardiology's 70th Annual Scientific Session. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 16, 2021 Category: Infectious Diseases Source Type: news
Farxiga Approved to Reduce Risk for CKD Progression
MONDAY, May 3, 2021 -- Farxiga (dapagliflozin) oral tablets are now approved for adults with chronic kidney disease at risk for disease progression, the U.S. Food and Drug Administration announced Friday.
The drug is the first to be approved to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 3, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves Dapagliflozin (Farxiga) for Chronic Kidney Disease FDA Approves Dapagliflozin (Farxiga) for Chronic Kidney Disease
Based on results of the DAPA-CKD trial, the FDA has granted approval for the diabetes drug in patients with CKD at risk for disease progression.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 30, 2021 Category: Cardiology Tags: Nephrology News Alert Source Type: news
Dapagliflozin, Advanced Chronic Kidney Disease, and Mortality Dapagliflozin, Advanced Chronic Kidney Disease, and Mortality
A report on the effects of the SGLT2 inhibitor dapagliflozin on morbidity and mortality in patients with chronic kidney disease suggests these drugs have potential beyond their original use in T2DM.European Heart Journal (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - April 28, 2021 Category: Intensive Care Tags: Nephrology Journal Article Source Type: news
New DAPA-CKD Analysis Hints at Dapagliflozin for IgA Nephropathy New DAPA-CKD Analysis Hints at Dapagliflozin for IgA Nephropathy
The landmark DAPA-CKD trial showed that dapagliflozin slows CKD progression regardless of diabetes status. Now a prespecified analysis suggests it also works for CKD patients with an IgA etiology.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - April 20, 2021 Category: Transplant Surgery Tags: Nephrology News Source Type: news
Dapagliflozin Quickly Reduces Heart Failure Events Dapagliflozin Quickly Reduces Heart Failure Events
A significant reduction of the incidence of cardiovascular death or worsening heart failure with dapagliflozin became apparent in DAPA-HF within 28 days after patients started treatment.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 23, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
AstraZeneca's Dapagliflozin tablets get DCGI nod for patients with chronic kidney disease
The company has "received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the DCGI for Dapagliflozin tablets 10 mg," AstraZeneca Pharma India said in a filing to BSE. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 6, 2021 Category: Pharmaceuticals Source Type: news
Drug Combo Offers Long-Term Glycemic Control in T2DM
FRIDAY, Nov. 6, 2020 -- For patients with type 2 diabetes and inadequate glycemic control, exenatide once weekly (QW) plus dapagliflozin shows clinically relevant efficacy and is well tolerated over 104 weeks, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 6, 2020 Category: Pharmaceuticals Source Type: news
Dapagliflozin Halves Hyperkalemia in Some HF Patients Dapagliflozin Halves Hyperkalemia in Some HF Patients
Dapagliflozin decreases moderate to severe hyperkalemia in heart failure (HF) patients treated with a mineralocorticoid receptor antagonist (MRA), a prespecified analysis of DAPA-HF data show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 29, 2020 Category: Consumer Health News Tags: Nephrology News Source Type: news
Dapagliflozin's CKD Performance Sends Heart Failure Messages Dapagliflozin's CKD Performance Sends Heart Failure Messages
The DAPA-CKD trial results have important messages for cardiologists, especially heart failure physicians.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 5, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
DAPA-CKD: SGLT2 Inhibitors'The Beta-Blockers for the Kidneys'DAPA-CKD: SGLT2 Inhibitors'The Beta-Blockers for the Kidneys '
Nephrologists Jennie Lin and Leslie Gewin discuss the effects of dapagliflozin in patients with CKD. How do the DAPA-CKD findings fit with the CREDENCE data on SGLT2 inhibitors?Medscape Nephrology (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 4, 2020 Category: Intensive Care Tags: Nephrology Commentary Source Type: news
SGLT2 inhibitors can slow progression of chronic kidney disease
(ERA-EDTA) The CREDENCE trial [3] provided evidence that the SGLT2 inhibitor Canagliflozin slows the progression of CKD in individuals with type 2 diabetes (T2D) and CKD with albuminuria. The Phase III DAPA-CKD trial [1] has now shown that the SGLT2 inhibitor Dapagliflozin can significantly slow CKD progression in all CKD patients, not only in those with diabetes. This breakthrough in kidney disease treatment goes back to an incidental study finding of Professor Christoph Wanner, President of the ERA-EDTA. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 31, 2020 Category: International Medicine & Public Health Source Type: news
DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes
DAPA-CKD showed that dapagliflozin helped patients with albuminuria and declining eGFR, whether or not they also had type 2 diabetes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 30, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
Empagliflozin's HFrEF Benefit Solidifies Class Effects Empagliflozin's HFrEF Benefit Solidifies Class Effects
The 25% cut in primary endpoints among patients with HFrEF receiving empagliflozin in EMPEROR-Reduced matched the benefit seen before from dapagliflozin in DAPA-HF.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 29, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
